Long-Acting Injectables Come of Age to Change the HIV Therapeutic Landscape and the Lives of Persons with HIV

Margolis DA , Brinson CC , Smith GH , et al.: Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE):a randomised, phase 2b, dose-ranging trial. Lancet ID, 2015; 15:1145–1155.

Margolis DA , Gonzalez-Garcia J , Stellbrink HJ , et al.: Spreen, Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. The Lancet, 2017, ISSN 0140-6736, http://dx.doi.org/10.1016/S0140-6736(17)31917-7

Swindells S , Andrade-Villanueva J-F , Richmond GJ , et al.: Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med, 2020; 382:1112–1123.

Orkin C , Arasteh K , Hernández-Mora MG , et al.: Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med, 2020; 382:1124–1135.

Overton ET , Richmond G , Rizzardini G , et al.: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. The Lancet, 2020; ISSN 0140-6736. https://doi.org/10.1016/S0140-6736(20)32666-0